CellType
Overview
The biological world model for drug development. CellType learns the hidden structure of cellular and molecular state, then turns it into decision systems for drug development.
Funding and backers
Backers
2
Y Combinator, Multimodal Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 2026
Went through Y Combinator
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
Psylink is a biotechnology company offering a novel solution to psychedelic drug development.
Avicenna Biosciences is a drug development company using machine learning-enhanced medicinal chemistry to accelerate the lead-to-candidate…
Perceptic connects evidence, data, decisions, and workflows across the drug development lifecycle, so every insight compounds.
Automated, high-sensitivity biomolecule analysis for drug development. Explore protein & RNA structure, stability, titer & more with…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Multimodal VenturesVia a fund
Y CombinatorVia a fund
6311 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understanding (MOU)
Read more
Report
(6492.TW) Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape ...
Read more
Report
Causal identification of single-cell experimental perturbation effects with CINEMA-OT
Recent advancements in single-cell technologies allow characterization of experimental perturbations at single-cell resolution. While methods have been developed to analyze such experiments, the application of a strict causal framework has not yet been ex
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
New York
United States
HQ